Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | Case report

Rituximab/temozolomide/zanubrutinib

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shi W, et al. Efficacy Analysis of Bruton's Tyrosine Kinase Inhibitor Combined Regimen in the Treatment of Elderly Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma Blood 140 (Suppl. 1): 12121, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-163377 [abstract] Shi W, et al. Efficacy Analysis of Bruton's Tyrosine Kinase Inhibitor Combined Regimen in the Treatment of Elderly Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma Blood 140 (Suppl. 1): 12121, Nov 2022. Available from: URL: https://​dx.​doi.​org/​10.​1182/​blood-2022-163377 [abstract]
Metadaten
Titel
Rituximab/temozolomide/zanubrutinib
Lack of efficacy
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-52127-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Zolpidem